Argenx SE has commenced a tender offer to acquire Forte Biosciences, Inc. in an all-cash transaction [1].
The deal allows the Amsterdam-based company to secure a promising autoimmune drug and broaden its existing immunology pipeline [2].
Under the terms of the agreement, Avena Merger Sub Inc., a wholly owned subsidiary of argenx, will purchase shares at $77 per share [1]. This pricing puts the total equity value of the transaction at approximately $2 billion [2].
The announcement was made from Amsterdam on July 27, 2024 [1]. This strategic move targets the acquisition of Forte's assets to strengthen the competitive position of argenx in the autoimmune sector [2].
Market data indicates that Forte Biosciences stock began showing significant price movement on June 29, 2024, nearly a month before the official acquisition announcement [3].
Argenx intends to integrate the acquired technology into its broader research and development goals. The company has not detailed the specific timeline for the full integration of Forte's operations following the completion of the tender offer [1].
“The all-cash transaction values Forte Biosciences at approximately $2 billion.”
This acquisition represents a significant consolidation in the immunology space. By absorbing Forte Biosciences, argenx is shifting from organic growth to aggressive acquisition to reduce the risk and time associated with early-stage drug development. The high premium paid per share suggests a strong belief in the clinical viability of Forte's specific autoimmune assets.
